COGT - CIK 0001622229
The table below shows Cogent Biosciences, Inc.'s balance sheet line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $312.01M | $98.17M | $53.23M | $139.89M | $219.68M | $242.19M |
| Short-term investments | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | $2.00M |
| Inventory | - | - | - | - | - | - |
| Total current assets |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $910.36M |
| $296.47M |
| $270.77M |
| $264.97M |
| $222.63M |
| $244.91M |
| Property, plant & equipment | $5.46M | $6.47M | $8.34M | $7.78M | $1.71M | $134.00K |
| Goodwill | - | - | - | - | - | - |
| Total assets | $937.61M | $327.90M | $313.44M | $300.81M | $232.09M | $250.92M |
| Accounts payable | $9.50M | $12.01M | $10.65M | $5.84M | $3.48M | $732.00K |
| Total current liabilities | $63.95M | $55.71M | $38.17M | $26.85M | $17.08M | $13.09M |
| Long-term debt | $222.90M | - | - | - | - | - |
| Total liabilities | $301.24M | $71.61M | $55.63M | $45.08M | $17.91M | $16.25M |
| Retained earnings | -$1.19B | -$859.48M | -$603.62M | -$411.21M | -$270.97M | -$198.70M |
| Total equity | $636.37M | $256.29M | $257.80M | $255.74M | $214.18M | $234.67M |